{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE297nnn/GSE297875/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297875"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of mouse breast cancer cell line 4T1 with cepharanthine for RNA-seq","description":"Breast cancer remains a significant global health challenge, with the highly aggressive 4T1 mouse mammary carcinoma cell line serving as a common model for studying triple-negative breast cancer (TNBC) due to its metastatic potential and resistance to therapy. Cepharanthine (CEP), a natural bisbenzylisoquinoline alkaloid, has demonstrated anti-inflammatory, immunomodulatory, and anti-cancer properties in various malignancies. However, its molecular mechanisms in 4T1 cells remain poorly understood. In this study, we treated 4T1 cells with CEP and performed RNA sequencing (RNA-seq) to elucidate transcriptomic alterations induced by this compound.","dates":{"publication":"2026/05/01"},"accession":"GSE297875","cross_references":{"GSM":["GSM9001391","GSM9001392","GSM9001393","GSM9001394","GSM9001395","GSM9001396"],"GPL":["24247"],"GSE":["297875"],"taxon":["Mus musculus"]}}